Retrovirology

official impact factor 5.24

Open Access Highly Access Research

HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment

Heiko Hauser1, Lisa A Lopez1, Su J Yang1, Jill E Oldenburg1, Colin M Exline1, John C Guatelli3,2 and Paula M Cannon1*

Author Affiliations

1 Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA

2 Department of Medicine, University of California San Diego, La Jolla, California, USA

3 San Diego Veterans Affairs Healthcare System, San Diego, California, USA

For all author emails, please log on.

Retrovirology 2010, 7:51 doi:10.1186/1742-4690-7-51

Published: 7 June 2010

Abstract

Background

In the absence of the Vpu protein, newly formed HIV-1 particles can remain attached to the surface of human cells due to the action of an interferon-inducible cellular restriction factor, BST-2/tetherin. Tetherin also restricts the release of other enveloped viral particles and is counteracted by a several viral anti-tetherin factors including the HIV-2 Env, SIV Nef and KSHV K5 proteins.

Results

We observed that a fraction of tetherin is located at the surface of restricting cells, and that co-expression of both HIV-1 Vpu and HIV-2 Env reduced this population. In addition, Vpu, but not the HIV-2 Env, reduced total cellular levels of tetherin. An additional effect observed for both Vpu and the HIV-2 Env was to redirect tetherin to an intracellular perinuclear compartment that overlapped with markers for the TGN (trans-Golgi network). Sequestration of tetherin in this compartment was independent of tetherin's normal endocytosis trafficking pathway.

Conclusions

Both HIV-1 Vpu and HIV-2 Env redirect tetherin away from the cell surface and sequester the protein in a perinuclear compartment, which likely blocks the action of this cellular restriction factor. Vpu also promotes the degradation of tetherin, suggesting that it uses more than one mechanism to counteract tetherin restriction.